{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:17:08Z","timestamp":1792318628901,"version":"4.4.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to investigate the effects of danthron on promoting megakaryocyte (MK) differentiation and alleviating thrombocytopenia, as well as to elucidate its underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cell proliferation and apoptosis of Meg-01 and K562 cells were evaluated by CCK-8, LDH release, and apoptosis assays. MK differentiation was assessed by Giemsa staining, phalloidin staining, and flow cytometry. A thrombocytopenia mouse model was induced by 4 Gy irradiation and treated intraperitoneally with danthron for 12 days, followed by hematological, histopathological, MK differentiation, and tail bleeding analyses. Potential targets and pathways were explored using network pharmacology, molecular docking, GO\/KEGG enrichment, Western blotting, and inhibitor validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Danthron effectively promoted MK differentiation\n                      <jats:italic>in vitro<\/jats:italic>\n                      , inducing the expression of MK differentiation\u2013related transcription factors NF-E2, RUNX1, MEIS1, and HIF-1\u03b2, without exhibiting significant cytotoxicity. In addition, danthron markedly accelerated the recovery of MK progenitors, MKs, and platelet levels in thrombocytopenic mice, and shortened tail bleeding time. These effects were associated with danthron directly targeting IL-6R and activating the downstream SRC\/RAS\/MAPK signaling pathway, whereas inhibition of IL-6R or ERK abrogated these effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study uncovered danthron as a novel natural small-molecule agonist of IL-6R and demonstrated its therapeutic potential in thrombocytopenia. The effect of danthron is mediated by its capacity to promote MK differentiation and induce platelet production through targeting of IL-6R and activation of the downstream SRC\/RAS\/MAPK signaling pathway. These results highlight danthron as a promising candidate for thrombocytopenia therapy and underscore the therapeutic potential of targeting IL-6R signaling for hematopoietic regulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1730028","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:19:20Z","timestamp":1774588760000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Danthron as a novel IL-6R agonist promotes thrombopoiesis via the SRC\/RAS\/MAPK pathway"],"prefix":"10.3389","volume":"17","author":[{"given":"Rui","family":"Liao","sequence":"first","affiliation":[{"name":"Sichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiesi","family":"Luo","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second People\u2019s Hospital of Yibin","place":["Yibin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Tang","sequence":"additional","affiliation":[{"name":"Sichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhou","sequence":"additional","affiliation":[{"name":"Sichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Yun","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Sichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peilian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Sichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinle","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Gan","sequence":"additional","affiliation":[{"name":"Sichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[{"name":"Sichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Southwest Medical University","place":["Luzhou, Sichuan, China"]},{"name":"Key Laboratory of Medical Electrophysiology, Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, (Collaborative Innovation Center for Prevention of Cardiovascular Diseases), Institute of Cardiovascular Research, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic Malignancies","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1667\/rr2610.1","article-title":"Development and licensure of medical countermeasures for platelet regeneration after radiation exposure","volume":"176","author":"DiCarlo","year":"2011","journal-title":"Radiat Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s13566-015-0201-z","article-title":"Role of thrombocytopenia in radiation-induced mortality and review of therapeutic approaches targeting platelet regeneration after radiation exposure","volume":"5","author":"DiCarlo","year":"2016","journal-title":"J Radiat Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05266-7","article-title":"Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective","volume":"102","author":"Yamasaki","year":"2023","journal-title":"Ann Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19940","article-title":"Corticosteroids plus metformin versus corticosteroids as front-line treatment for patients with newly diagnosed ITP and pre-existing type 2 diabetes mellitus: a multicentre propensity score-matched study","volume":"206","author":"Hou","year":"2024","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/hematolrep16030039","article-title":"Treatment of immune thrombocytopenia: contextualization from a historical perspective","volume":"16","author":"Mart\u00ednez-Carballeira","year":"2024","journal-title":"Hematol Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179615","article-title":"Megakaryopoiesis and platelet biology: roles of transcription factors and emerging clinical implications","volume":"22","author":"Noh","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.07.037","article-title":"Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis","volume":"186","author":"Tsutsumi","year":"2023","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2711313","article-title":"Insights into regulatory factors in megakaryocyte development and function: basic mechanisms and potential targets","volume":"27","author":"Li","year":"2022","journal-title":"Front Biosci (Landm Ed)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201410052","article-title":"IL-1\u03b1 induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs","volume":"209","author":"Nishimura","year":"2015","journal-title":"J Cell Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1404354111","article-title":"Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation","volume":"111","author":"Ng","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.exphem.2020.07.006","article-title":"Erythropoietin is a major regulator of thrombopoiesis in thrombopoietin-dependent and -independent contexts","volume":"88","author":"Hacein-Bey-Abina","year":"2020","journal-title":"Exp Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2019.02.005","article-title":"Difference in megakaryocyte expression of GATA-1, IL-6, and IL-8 associated with maintenance of platelet counts in patients with plasma cell neoplasm with dysmegakaryopoiesis","volume":"73","author":"Kim","year":"2019","journal-title":"Exp Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cells14110766","article-title":"IL-6 as a mediator of platelet hyper-responsiveness","volume":"14","author":"Webb","year":"2025","journal-title":"Cells"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1442297","article-title":"The application of rhubarb concoctions in traditional chinese medicine and its compounds, processing methods, pharmacology, toxicology and clinical research","volume":"15","author":"Wen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116562","article-title":"Effects of rheum rhaponticum and rheum rhabarbarum extracts on haemostatic activity of blood plasma components and endothelial cells in vitro","volume":"315","author":"Liudvytska","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.942657","article-title":"Efficacy and safety of traditional chinese medicine for intracranial hemorrhage by promoting blood circulation and removing blood stasis: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Lin","year":"2022","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0045-1806864","article-title":"Interpretation of the pathological mechanism of blood stasis in traditional chinese medicine in light of understanding of hypercoagulable states in modern medicine","volume":"5","author":"Chen","year":"2025","journal-title":"Chin Med Natural Pro"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2019.01.027","article-title":"A network pharmacology approach to investigate the blood enriching mechanism of Danggui buxue decoction","volume":"235","author":"Shi","year":"2019","journal-title":"J Ethnopharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3790728","article-title":"Neuroprotective effects of anthraquinones from rhubarb in central nervous system diseases","volume":"2019","author":"Li","year":"2019","journal-title":"Evid Based Complem Alternat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1113\/ep089021","article-title":"Danthron attenuates experimental atherosclerosis by targeting foam cell formation","volume":"106","author":"Shi","year":"2021","journal-title":"Exp Physiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13020-017-0158-5","article-title":"Advances in bio-active constituents, pharmacology and clinical applications of rhubarb","volume":"12","author":"Cao","year":"2017","journal-title":"Chin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1055\/a-2689-7785","article-title":"EFCAB13 is a novel age-dependent promotor of SOCE in blood platelets and megakaryoblastic MEG-01 cells","author":"Redondo","year":"2025","journal-title":"Thromb Haemost"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2022.11.007","article-title":"Histone deacetylation-regulated cell surface Siglec-7 expression promoted megakaryocytic maturation and enhanced platelet-like particle release","volume":"21","author":"Huang","year":"2023","journal-title":"J Thromb Haemost"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15329","article-title":"RUNX1 and TGF-\u03b2 signaling cross talk regulates Ca2+ ion channels expression and activity during megakaryocyte development","volume":"287","author":"Raghuwanshi","year":"2020","journal-title":"FEBS J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000185","article-title":"Pivotal role of PDK1 in megakaryocyte cytoskeletal dynamics and polarization during platelet biogenesis","volume":"134","author":"Geue","year":"2019","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/09537104.2010.541959","article-title":"GSK-3\u03b2 negatively regulates megakaryocyte differentiation and platelet production from primary human bone marrow cells in vitro","volume":"22","author":"Ono","year":"2011","journal-title":"Platelets"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008591","article-title":"A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation","volume":"7","author":"Wang","year":"2023","journal-title":"Blood Adv"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.2289.2289","article-title":"C-MYC and NF-E2 genes regulate proplatelet formation in cultured megakaryocytes with different levels of polyploidization","volume":"120","author":"Avanzi","year":"2012","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.106567","article-title":"MEIS1 regulates early erythroid and megakaryocytic cell fate","volume":"99","author":"Zeddies","year":"2014","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282209","article-title":"Targeting a thrombopoietin-independent strategy in the discovery of a novel inducer of megakaryocytopoiesis, DMAG, for the treatment of thrombocytopenia","volume":"108","author":"Wang","year":"2023","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.119.312129","article-title":"New insights into the differentiation of megakaryocytes from hematopoietic progenitors","volume":"39","author":"Noetzli","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012827","article-title":"The bone marrow niche from the inside out: how megakaryocytes are shaped by and shape hematopoiesis","volume":"139","author":"Stone","year":"2022","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci153920","article-title":"Sepsis promotes splenic production of a protective platelet pool with high CD40 ligand expression","volume":"132","author":"Valet","year":"2022","journal-title":"J\u00a0Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2020.1841893","article-title":"Regulation of platelet numbers and sizes by signaling pathways","volume":"32","author":"Pawinwongchai","year":"2021","journal-title":"Platelets"},{"key":"B36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/cancers16010032","article-title":"Role of c-Src in carcinogenesis and drug resistance","volume":"16","author":"Raji","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Bas Clin Pharm"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000505099","article-title":"Interleukin-6: a masterplayer in the cytokine network","volume":"98","author":"Uciechowski","year":"2020","journal-title":"Oncology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1730028\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:19:22Z","timestamp":1774588762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1730028\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1730028"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1730028","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"1730028"}}